MX391356B - Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo - Google Patents

Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo

Info

Publication number
MX391356B
MX391356B MX2020010365A MX2020010365A MX391356B MX 391356 B MX391356 B MX 391356B MX 2020010365 A MX2020010365 A MX 2020010365A MX 2020010365 A MX2020010365 A MX 2020010365A MX 391356 B MX391356 B MX 391356B
Authority
MX
Mexico
Prior art keywords
sup
hydroxyalkyl
phenyl
producing
triazole
Prior art date
Application number
MX2020010365A
Other languages
English (en)
Spanish (es)
Other versions
MX2020010365A (es
Inventor
Chantal Fürstner
Frank Süssmeier
Hans - Christian Militzer
Heiko Schirmer
Kersten Matthias Gericke
Marie - Pierre COLLIN-KRÖPELIN
Philipp Rubenbauer
Thomas Neubauer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2020010365A publication Critical patent/MX2020010365A/es
Publication of MX391356B publication Critical patent/MX391356B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2020010365A 2016-05-03 2017-05-02 Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo MX391356B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16168169 2016-05-03
EP16168172 2016-05-03
EP16168165 2016-05-03
EP16168166 2016-05-03
EP16168163 2016-05-03
EP17160086 2017-03-09
PCT/EP2017/060367 WO2017191104A1 (de) 2016-05-03 2017-05-02 Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen

Publications (2)

Publication Number Publication Date
MX2020010365A MX2020010365A (es) 2022-04-06
MX391356B true MX391356B (es) 2025-03-19

Family

ID=58633014

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020010365A MX391356B (es) 2016-05-03 2017-05-02 Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
MX2018013336A MX379555B (es) 2016-05-03 2017-05-02 Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018013336A MX379555B (es) 2016-05-03 2017-05-02 Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo.

Country Status (18)

Country Link
US (2) US10703742B2 (OSRAM)
EP (1) EP3452467A1 (OSRAM)
JP (2) JP6921863B2 (OSRAM)
KR (1) KR20190003536A (OSRAM)
CN (2) CN109071500B (OSRAM)
AU (2) AU2017259872B2 (OSRAM)
BR (1) BR112018072528A2 (OSRAM)
CA (1) CA3022789A1 (OSRAM)
CL (1) CL2018003107A1 (OSRAM)
CO (1) CO2018011948A2 (OSRAM)
IL (1) IL262534B (OSRAM)
MX (2) MX391356B (OSRAM)
PE (1) PE20190202A1 (OSRAM)
RU (1) RU2742885C2 (OSRAM)
SG (1) SG11201809672YA (OSRAM)
TW (1) TWI755393B (OSRAM)
UY (1) UY37222A (OSRAM)
WO (1) WO2017191104A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191115A1 (en) * 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
TWI755393B (zh) * 2016-05-03 2022-02-21 德商拜耳製藥股份有限公司 製備5-羥基烷基取代之1-苯基-1,2,4-三唑衍生物之方法
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653332A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
WO2011104322A1 (de) * 2010-02-27 2011-09-01 Bayer Pharma Aktiengesellschaft Bis-arylverknüpfte aryltriazolone und ihre verwendung
ES2641205T3 (es) * 2012-05-08 2017-11-08 Bayer Pharma Aktiengesellschaft Procedimiento para la preparación de compuestos de triazol
CN107074783B (zh) * 2014-11-03 2020-06-05 拜耳制药股份公司 羟烷基取代的苯基三唑衍生物及其用途
WO2017191115A1 (en) * 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
TWI755393B (zh) * 2016-05-03 2022-02-21 德商拜耳製藥股份有限公司 製備5-羥基烷基取代之1-苯基-1,2,4-三唑衍生物之方法
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof

Also Published As

Publication number Publication date
CN113105403A (zh) 2021-07-13
TW201815782A (zh) 2018-05-01
MX2018013336A (es) 2019-05-09
KR20190003536A (ko) 2019-01-09
WO2017191104A1 (de) 2017-11-09
US10703742B2 (en) 2020-07-07
RU2018142264A (ru) 2020-06-03
JP2021143193A (ja) 2021-09-24
CN109071500A (zh) 2018-12-21
EP3452467A1 (de) 2019-03-13
AU2017259872B2 (en) 2021-06-24
SG11201809672YA (en) 2018-11-29
CA3022789A1 (en) 2017-11-09
UY37222A (es) 2017-11-30
CL2018003107A1 (es) 2019-02-22
JP6921863B2 (ja) 2021-08-18
BR112018072528A2 (pt) 2019-03-26
IL262534B (en) 2021-04-29
MX379555B (es) 2025-03-11
CO2018011948A2 (es) 2018-11-22
CN109071500B (zh) 2021-05-18
RU2742885C2 (ru) 2021-02-11
JP2019514948A (ja) 2019-06-06
AU2021236502A1 (en) 2021-10-21
US20190144431A1 (en) 2019-05-16
TWI755393B (zh) 2022-02-21
AU2017259872A1 (en) 2018-11-22
RU2018142264A3 (OSRAM) 2020-08-19
MX2020010365A (es) 2022-04-06
IL262534A (en) 2018-12-31
US20200299271A1 (en) 2020-09-24
PE20190202A1 (es) 2019-02-05

Similar Documents

Publication Publication Date Title
MX2020010365A (es) Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo.
IL281196A (en) Process for the preparation of methyl 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo[ 7]Anolene-2-carboxylate
NZ595553A (en) VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol
IL259609A (en) Method for producing 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(4,2,1-triazol-1-yl)propan-2-ol
JO3062B1 (ar) R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
CL2014000384A1 (es) Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-alcoxi-2-alquinil/alquenil-etil)-1h-(1,2,4) triazol sustituidos; proceso para preparar dichos compuestos; composiciones agroquímicas.
HRP20160172T1 (hr) Spojevi koji su inhibitori metaloenzima
EA023517B1 (ru) Модуляторы глюкагонового рецептора
SI2740731T1 (sl) Kristalinične soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopen tilpropannitrila
CL2014000534A1 (es) Procesos para preparar {1-{1-[3-fluoro-2-(trifluorometil)isonicotinoil]piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo y compuestos intermediarios, inhibidores de jak; y compuesto intermediario (3-fluoro-2-(trifluorometil)piridin-4-il)(1,4-dioxa-8-azaspiro[4,5]decan-8-il)metanona.
MX2007008784A (es) Derivados de pirazol para la inhibicion de las cdks y gsks.
JP2008546753A5 (OSRAM)
MX2023009857A (es) Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos.
IL285675A (en) Crystalline form of 1-(1-oxo-2,1-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
EP3377480A4 (en) 4 - ((6- (2,4-DIFLUROPHENYL) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-YL) PROPYL) PYRIDINE-3-YL) OXY ) BENZONITRILE AND METHOD OF PREPARING THEREOF
NZ624636A (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
MY184577A (en) Method for the preparation of triazole compounds
GB2450268B (en) Synthesis of 4-[1-(4-cyano phenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile and 4-[1-(1,2,4-triazol-1-yl)methyl]benzonitrile intermediate
MY198496A (en) Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4- triazole derivatives
WO2007013096A8 (en) Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole)
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
IL291569A (en) Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-4,2,1-triazol-3-amine
IL314283A (en) Methods for preparing ethyl 3-bromo-1-(3-chloropyridin-2-yl)-5,4-dihydro-H1-pyrazole-5-carboxylate
HK40065506A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate